Currency In USD
| Previous Close | 1.32 |
| Open | 1.29 |
| Day High | 1.31 |
| Day Low | 1.28 |
| 52-Week High | 7.08 |
| 52-Week Low | 1.27 |
| Volume | 15,013 |
| Average Volume | 772,951 |
| Market Cap | 165.22M |
| PE | 42.8 |
| EPS | 0.03 |
| Moving Average 50 Days | 1.7 |
| Moving Average 200 Days | 2.69 |
| Change | -0.04 |
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 19, 2026 9:05 PM GMT
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and
Organogenesis Announces Initiation of Biologics License Application for ReNu®
GlobeNewswire Inc.
Dec 23, 2025 9:05 PM GMT
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on t
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
GlobeNewswire Inc.
Dec 15, 2025 9:25 PM GMT
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the dev